Ligand Pharmaceuticals Incorporated (LGND) Insider Trading
- $6,495,870.39
- $219,511,111.93
- July 10, 2025
- John L Higgins
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| Aug. 23, 2017 | Director | 2,000 | $127.99 | Sell | $255,980.00 | |
| Aug. 9, 2017 | VP | 18,625 | $126.96 | Sell | $2,364,630.00 | |
| Aug. 9, 2017 | Insider | 6,100 | $127.51 | Sell | $777,811.00 | |
| Aug. 8, 2017 | CEO | 5,483 | $125.00 | Sell | $685,375.00 | |
| June 21, 2017 | CEO | 4,666 | $120.00 | Sell | $559,920.00 | |
| June 9, 2017 | CEO | 12,000 | $114.87 | Sell | $1,378,440.00 | |
| May 12, 2017 | Insider | 5,621 | $112.20 | Sell | $630,676.20 | |
| May 12, 2017 | Director | 37,247 | $110.76 | Sell | $4,125,477.72 | |
| March 20, 2017 | CEO | 4,000 | $109.10 | Sell | $436,400.00 | |
| March 2, 2017 | Insider | 6,879 | $103.39 | Sell | $711,219.81 | |
| Feb. 28, 2017 | Director | 32,000 | $106.35 | Sell | $3,403,200.00 | |
| Nov. 25, 2016 | Director | 18,479 | $107.31 | Sell | $1,982,981.49 | |
| Nov. 18, 2016 | Director | 6,330 | $105.28 | Sell | $666,422.40 | |
| Sept. 22, 2016 | CEO | 3,000 | $117.34 | Sell | $352,020.00 | |
| Sept. 7, 2016 | Director | 1,000 | $115.00 | Sell | $115,000.00 | |
| Sept. 1, 2016 | Director | 1,666 | $105.40 | Sell | $175,596.40 | |
| Aug. 1, 2016 | Director | 1,000 | $137.57 | Sell | $137,570.00 | |
| July 1, 2016 | Director | 1,000 | $121.40 | Sell | $121,400.00 | |
| June 1, 2016 | Director | 1,000 | $117.42 | Sell | $117,420.00 | |
| May 18, 2016 | Director | 334 | $120.50 | Sell | $40,247.00 | |
| May 6, 2016 | Director | 25,000 | $119.20 | Sell | $2,980,000.00 | |
| May 2, 2016 | Director | 1,000 | $121.57 | Sell | $121,570.00 | |
| April 6, 2016 | Director | 5,000 | $115.00 | Sell | $575,000.00 | |
| March 17, 2016 | COO | 6,400 | $96.70 | Sell | $618,880.00 | |
| March 8, 2016 | Director | 6,129 | $101.18 | Sell | $620,132.22 | |
| March 7, 2016 | CEO | 10,833 | $102.47 | Sell | $1,110,057.51 | |
| Jan. 20, 2016 | Director | 1,666 | $94.94 | Sell | $158,170.04 | |
| Nov. 11, 2015 | Director | 7,719 | $101.00 | Sell | $779,619.00 | |
| Aug. 17, 2015 | Director | 4,000 | $95.98 | Sell | $383,920.00 | |
| Aug. 13, 2015 | Director | 49,800 | $96.26 | Sell | $4,793,748.00 | |
| July 10, 2015 | VP | 14,067 | $99.14 | Sell | $1,394,602.38 | |
| June 26, 2015 | COO | 12,500 | $100.97 | Sell | $1,262,125.00 | |
| June 22, 2015 | COO | 23,046 | $96.45 | Sell | $2,222,786.70 | |
| June 10, 2015 | CFO | 4,125 | $93.50 | Sell | $385,687.50 | |
| June 9, 2015 | CEO | 10,000 | $92.88 | Sell | $928,800.00 | |
| June 4, 2015 | Director | 1,640 | $92.68 | Sell | $151,995.20 | |
| May 20, 2015 | Director | 9,240 | $87.34 | Sell | $807,021.60 | |
| May 14, 2015 | CFO | 68,363 | $83.91 | Sell | $5,736,339.33 | |
| March 19, 2015 | Director | 4,591 | $74.42 | Sell | $341,662.22 | |
| Feb. 10, 2015 | VP | 2,300 | $56.34 | Sell | $129,582.00 | |
| Oct. 15, 2014 | Director | 2,000 | $45.68 | Buy | $91,360.00 | |
| Oct. 9, 2014 | Director | 11,000 | $42.99 | Buy | $472,890.00 | |
| Aug. 15, 2014 | CEO | 1,000 | $54.97 | Buy | $54,970.00 | |
| June 9, 2014 | Director | 1,100 | $69.68 | Sell | $76,648.00 | |
| May 27, 2014 | VP | 7,166 | $66.90 | Sell | $479,405.40 | |
| March 25, 2014 | Insider | 78,226 | $70.09 | Sell | $5,482,860.34 | |
| March 19, 2014 | Director | 7,500 | $79.57 | Sell | $596,775.00 | |
| March 18, 2014 | Director | 5,000 | $78.83 | Sell | $394,150.00 | |
| Feb. 20, 2014 | major shareholder | 422,900 | $73.81 | Sell | $31,214,249.00 | |
| Feb. 18, 2014 | Director | 41,900 | $75.71 | Sell | $3,172,249.00 |
Insiders are both buying and selling Ligand Pharmaceuticals Incorporated stock.
The insider traders at Ligand Pharmaceuticals Incorporated are: Matthew W Foehr, John L Higgins, Jason Aryeh, John W Kozarich, Octavio Espinoza, Charles S Berkman, Matthew E Korenberg, Todd C Davis, Andrew Reardon, Stephen L Sabba, Bvf Partners L P/Il, John L Lamattina, David M Knott, Melanie J Herman, Bvf Partners P/Il, Nishan M Desilva, Sunil Patel, David Knott, Matthew Foehr, Charles Berkman, John Sharp, Todd Davis, John Higgins, John W. Kozarich, Melanie J. Herman, and John Lamattina
The most active insider trader at Ligand Pharmaceuticals Incorporated is Matthew W Foehr with 27 trades.
Bvf Partners P/Il has sold the most Ligand Pharmaceuticals Incorporated stock with a total value of $58,156,493.18.
Bvf Partners L P/Il has bought the most Ligand Pharmaceuticals Incorporated stock with a total value of $2,817,728.47.
The most recent insider trade for Ligand Pharmaceuticals Incorporated was on July 10, 2025.
The single biggest insider buy for Ligand Pharmaceuticals Incorporated was from Todd C Davis with a total value of $1,000,452.00 on May 9, 2025.
The single biggest insider sell for Ligand Pharmaceuticals Incorporated was from Bvf Partners P/Il with a total value of $31,214,249.00 on Feb. 20, 2014.